Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats

Table 2 Effect of pre-treatment of rosiglitazone with cisplatin on tumour volume (cm) in chemically induced breast cancer model

	0 Day	3^rd Day	6^th Day	9^th Day
Normal control	0 ± 0	0 ± 0	0 ± 0	0 ± 0
Breast cancer control	2.3 ± 1.04	4.33 ± 0.99	5.85 ± 1.16	6.5 ± 1.46
Rosi (8 mg/kg)	2.26 ± 0.48	1.94 ± 0.61	1.89 ± 0.73**^a	1.85 ± 0.19**^a
Cis (7.5 mg/kg)	2.23 ± 0.57	1.85 ± 0.44	1.62 ± 0.41**^a	1.53 ± 0.35***^a
PT Rosi (8 mg/kg) + Cis (7.5 mg/kg)	2.06 ± 0.84	1.63 ± 0.56*^a	1.25 ± 0.46**^a	0.98 ± 0.36***^a

All values are expressed as mean ± SEM (n = 8). ***P < 0.001, **<0.01, *P < 0.05. a Vs Cancer Control. Where Rosi is rosiglitazone, Cis is cisplatin and PT is pretreatment

ISSN: 1471-2407